Clinical course and management of pembrolizumab-associated isolated adrenocorticotrophic hormone deficiency: a new case and literature review.
Immunotherapy
; 13(14): 1157-1163, 2021 10.
Article
in En
| MEDLINE
| ID: mdl-34387129
Lay abstract Immune check point inhibitors (ICIs) are used in order to enhance antitumoral immune mechanisms in certain cancers. As a result, immune-related side effects have commonly been reported in patients taking ICIs, one of which is hypophysitis. Pembrolizumab is a type of ICI which has rarely been associated with hypophysitis. Since the clinical presentation of pembrolizumab-associated hypophysitis is usually as isolated adrenocorticotrophic hormone deficiency and related cortisol insufficiency, patients may be misjudged as having clinical symptoms due to cancer or chemotherapy, due to shared symptoms such as fatigue, loss of appetite and nausea. Here we have reported a case with pembrolizumab-associated isolated adrenocorticotrophic hormone deficiency and reviewed all other cases available in the literature to improve our understanding of such patients.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Laryngeal Neoplasms
/
Adrenocorticotropic Hormone
/
Antibodies, Monoclonal, Humanized
/
Hypophysitis
/
Squamous Cell Carcinoma of Head and Neck
/
Immune Checkpoint Inhibitors
Type of study:
Risk_factors_studies
Limits:
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Immunotherapy
Journal subject:
ALERGIA E IMUNOLOGIA
/
TERAPEUTICA
Year:
2021
Document type:
Article
Affiliation country:
Turquía